Marina Biotech (MRNA) 1.0000 $MRNA
Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences
Marketwire - Wed Sep 03, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.
Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
Marketwire - Wed Aug 20, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2012 and December 31, 2013, its Quarterly Reports on Form 10-Q for the first three quarters of the 2013 fiscal year, and its Quarterly Reports on Form 10-Q for the first and second fiscal quarters of 2014 over the past thirty days. In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
Marketwire - Thu Jun 12, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company's licensee, Mirna Therapeutics, has reported that Mirna enrolled the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34. MRX34 is Mirna's lead product candidate and first microRNA mimic in human clinical trials in the oncology space. Under terms of the license agreement, Mirna has full responsibility for the development and commercialization of any products which arise during the license period, and Marina Biotech could receive up to $60 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases
Marketwire - Wed Apr 02, 8:09AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.
Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
Marketwire - Tue Mar 11, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it plans to broadly apply its RNAi, antisense and microRNA therapeutics platform to develop drugs for rare diseases. Besides advancing its current Phase 1 program in Familial Adenomatous Polyposis, the company expects to initially focus on the area of dystrophies where it believes its broad capabilities including its conformationally restricted nucleotide (CRN) chemistry and SMARTICLES(R) delivery technology can provide an advantage over existing nucleic acid therapeutic approaches. J. Michael French, CEO of Marina Biotech will present an overview of the company's plans today at BIO-Europe Spring(R) 2014 in Turin, Italy.
Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology
Marketwire - Thu Feb 27, 6:45AM CST
Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today that a decision to grant a patent has been issued for the Company's fundamental SMARTICLES(R) delivery technology in Japan (Ser. No. 2010-211089). The claims of this National Stage Application cover fundamental amphoteric liposomes made with preferred amphipathic components, and are a combination of a weak, but variable, anionic charge carrier and a weak cationic charge carrier. The granted claims cover amphoteric liposomes that are suitable for designing specific formulation systems for both the controlled- and sustained-release of nucleic acid therapeutic cargos, including RNA, DNA, antisense and nucleic acid decoys. In addition, the granted claims cover pharmaceutical preparations made from the amphoteric liposomes, a key to successful commercialization of the therapeutics.
MRNA Marina Biotech Share Volume and Value Soar on Rumors of Patents and Presentations
ACCESSWIRE - Tue Feb 25, 8:25AM CST
Sometimes small companies that remain silent become the object of investors more so than those penny stocks that issue press releases daily.
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note
Marketwire - Mon Feb 24, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today that it has entered into a binding term sheet with certain qualified investors, led by Steven T. Newby, a long-time biotechnology investor, for the issuance of convertible preferred stock at a conversion price equivalent to $0.75 per share of common stock resulting in gross proceeds of $6 million. In addition, the Company will issue to the investors warrants to purchase 6 million shares of common stock. The warrants will have an exercise price of $0.75 per share and are exercisable for a period of five years after the Company regains compliance with its reporting obligations under the Securities Exchange Act. The offering is expected to close on or about March 7, 2014, subject to the execution of a customary Securities Purchase Agreement regarding the transaction and the satisfaction of customary closing conditions. The Company also announced that the holders of the Company's Promissory Note have agreed to convert the remaining principal and interest on the Note to common stock at a conversion price of $0.75 and release their lien on the Company's intellectual property. Proceeds from the financing will be used to restart certain day-to-day operations, repay the Company's outstanding obligations, regain compliance with the Company's Exchange Act reporting obligations and advance the Company's preclinical and clinical rare disease programs.
Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan
Marketwire - Thu Jan 23, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that a decision to grant a patent has been issued for the Company's Di-alkylated Amino Acid (DiLA2) liposomal delivery technology in Japan (Ser No 2010-506690). The claims of this National Stage Application broadly cover DiLA2 compounds, as well as compositions containing therapeutic nucleic acids, and uses for treating a wide range of diseases. The patent claims granted in Japan cover norarginine- and pyridylalanine-based compounds, which are known to be some of the most efficacious liposome-forming compounds developed by Marina Biotech for delivery of nucleic acid-based therapeutics. In addition, the European Patent Office has agreed to the allowance of broad DiLA2 patent claims, which will be granted. A DiLA2 patent has previously been issued in the U.S. and China. Thus, with the decision to grant from the Japan Patent Office, Marina Biotech has achieved broad coverage for the DiLA2 patent estate in the four largest commercial markets.
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology
Marketwire - Tue Jan 14, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance in Canada Patent Application 2,591,565, for "Compositions for Bacterial Mediated Gene Silencing and Methods of Use." This patent allowance supports the Company's transkingdom RNAi (tkRNAi) nucleic acid delivery technology. The tkRNAi technology is an integral part of the Company's broad nucleic acid-based drug discovery platform and was utilized in the development of CEQ508 for the potential treatment of Familial Adenomatous Polyposis (FAP). CEQ508 has thus far been orally administered in two cohorts of a four cohort dose-escalating study in a Phase 1 human clinical trial in FAP patients. The Company has received U.S. Food and Drug Administration Orphan Drug Designation for this program.
Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES(R) Nucleic Acid Delivery Technology
Marketwire - Thu Jan 09, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today the grant and issuance of patents relating to the Company's proprietary nucleic-acid delivery technology, SMARTICLES(R). The U.S. Patent and Trademark Office (USPTO) has issued United States Patent No. 8,580,297 (the "US '297 patent"
broadly covering the composition of matter and uses of novel conjugated amphoteric-amphiphilic molecules for delivery of nucleic acid-based therapeutics to control gene expression. In addition, the Japan Patent Office (JPO) has granted the claims in SMARTICLES(R) JP Application 2009-531787 (the "JP '787 application" broadly covering the combination of an anionic amphiphile, a cationic amphiphile, and a neutral amphiphile with parameters that cover a wide range of liposomal compositions. SMARTICLES is currently in clinical development delivering both a single-stranded and a double-stranded oligonucleotide through licensees ProNAi Therapeutics, Inc. and Mirna Therapeutics, Inc., respectively.
Marina Biotech Announces Organizational Changes
Marketwire - Fri Jan 03, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that Philip C. Ranker will join the Marina Biotech Board of Directors and that Richard T. Ho, M.D., Ph.D., will become the Chair of the Marina Biotech Scientific Advisory Board. Further, in an on-going effort to conserve resources as the company focuses on near term pharma collaboration opportunities, Mr. Ranker and Dr. Ho have resigned from their respective positions, Interim Chief Financial Officer and Executive Vice President, Research and Development, to pursue other opportunities. The finance function of the company will transition to an outside service provider.
Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics
Marketwire - Thu Jan 02, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology. Under terms of the amendment, Mirna paid certain pre-payments to Marina Biotech and now has additional rights to its lead program, MRX34, currently in Phase 1 clinical development for patients with unresectable primary liver cancer or metastatic cancer with liver involvement. In addition, under the terms of the license agreement, Mirna has optioned exclusivity on several additional miRNA targets. Further terms of the Agreement were not disclosed.
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Marina Biotech Monetizes UNA Intellectual Property Estate Through Agreement With Arcturus Therapeutics
Marketwire - Wed Aug 14, 6:00AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA)
Myotonic Dystrophy - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zlztxh/myotonic) has announced the addition of the "Myotonic Dystrophy - Pipeline Review, H1 2013" report to their offering. 'Myotonic Dystrophy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myotonic Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myotonic Dystrophy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Myotonic Dystrophy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Myotonic D
Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34
Marketwire - Mon May 13, 7:01AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.
Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences
Marketwire - Wed Sep 03, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.
Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
Marketwire - Wed Aug 20, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2012 and December 31, 2013, its Quarterly Reports on Form 10-Q for the first three quarters of the 2013 fiscal year, and its Quarterly Reports on Form 10-Q for the first and second fiscal quarters of 2014 over the past thirty days. In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
Marketwire - Thu Jun 12, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company's licensee, Mirna Therapeutics, has reported that Mirna enrolled the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34. MRX34 is Mirna's lead product candidate and first microRNA mimic in human clinical trials in the oncology space. Under terms of the license agreement, Mirna has full responsibility for the development and commercialization of any products which arise during the license period, and Marina Biotech could receive up to $60 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases
Marketwire - Wed Apr 02, 8:09AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.
Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
Marketwire - Tue Mar 11, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it plans to broadly apply its RNAi, antisense and microRNA therapeutics platform to develop drugs for rare diseases. Besides advancing its current Phase 1 program in Familial Adenomatous Polyposis, the company expects to initially focus on the area of dystrophies where it believes its broad capabilities including its conformationally restricted nucleotide (CRN) chemistry and SMARTICLES(R) delivery technology can provide an advantage over existing nucleic acid therapeutic approaches. J. Michael French, CEO of Marina Biotech will present an overview of the company's plans today at BIO-Europe Spring(R) 2014 in Turin, Italy.
Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology
Marketwire - Thu Feb 27, 6:45AM CST
Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today that a decision to grant a patent has been issued for the Company's fundamental SMARTICLES(R) delivery technology in Japan (Ser. No. 2010-211089). The claims of this National Stage Application cover fundamental amphoteric liposomes made with preferred amphipathic components, and are a combination of a weak, but variable, anionic charge carrier and a weak cationic charge carrier. The granted claims cover amphoteric liposomes that are suitable for designing specific formulation systems for both the controlled- and sustained-release of nucleic acid therapeutic cargos, including RNA, DNA, antisense and nucleic acid decoys. In addition, the granted claims cover pharmaceutical preparations made from the amphoteric liposomes, a key to successful commercialization of the therapeutics.
MRNA Marina Biotech Share Volume and Value Soar on Rumors of Patents and Presentations
ACCESSWIRE - Tue Feb 25, 8:25AM CST
Sometimes small companies that remain silent become the object of investors more so than those penny stocks that issue press releases daily.
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note
Marketwire - Mon Feb 24, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today that it has entered into a binding term sheet with certain qualified investors, led by Steven T. Newby, a long-time biotechnology investor, for the issuance of convertible preferred stock at a conversion price equivalent to $0.75 per share of common stock resulting in gross proceeds of $6 million. In addition, the Company will issue to the investors warrants to purchase 6 million shares of common stock. The warrants will have an exercise price of $0.75 per share and are exercisable for a period of five years after the Company regains compliance with its reporting obligations under the Securities Exchange Act. The offering is expected to close on or about March 7, 2014, subject to the execution of a customary Securities Purchase Agreement regarding the transaction and the satisfaction of customary closing conditions. The Company also announced that the holders of the Company's Promissory Note have agreed to convert the remaining principal and interest on the Note to common stock at a conversion price of $0.75 and release their lien on the Company's intellectual property. Proceeds from the financing will be used to restart certain day-to-day operations, repay the Company's outstanding obligations, regain compliance with the Company's Exchange Act reporting obligations and advance the Company's preclinical and clinical rare disease programs.
Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan
Marketwire - Thu Jan 23, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that a decision to grant a patent has been issued for the Company's Di-alkylated Amino Acid (DiLA2) liposomal delivery technology in Japan (Ser No 2010-506690). The claims of this National Stage Application broadly cover DiLA2 compounds, as well as compositions containing therapeutic nucleic acids, and uses for treating a wide range of diseases. The patent claims granted in Japan cover norarginine- and pyridylalanine-based compounds, which are known to be some of the most efficacious liposome-forming compounds developed by Marina Biotech for delivery of nucleic acid-based therapeutics. In addition, the European Patent Office has agreed to the allowance of broad DiLA2 patent claims, which will be granted. A DiLA2 patent has previously been issued in the U.S. and China. Thus, with the decision to grant from the Japan Patent Office, Marina Biotech has achieved broad coverage for the DiLA2 patent estate in the four largest commercial markets.
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology
Marketwire - Tue Jan 14, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance in Canada Patent Application 2,591,565, for "Compositions for Bacterial Mediated Gene Silencing and Methods of Use." This patent allowance supports the Company's transkingdom RNAi (tkRNAi) nucleic acid delivery technology. The tkRNAi technology is an integral part of the Company's broad nucleic acid-based drug discovery platform and was utilized in the development of CEQ508 for the potential treatment of Familial Adenomatous Polyposis (FAP). CEQ508 has thus far been orally administered in two cohorts of a four cohort dose-escalating study in a Phase 1 human clinical trial in FAP patients. The Company has received U.S. Food and Drug Administration Orphan Drug Designation for this program.
Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES(R) Nucleic Acid Delivery Technology
Marketwire - Thu Jan 09, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today the grant and issuance of patents relating to the Company's proprietary nucleic-acid delivery technology, SMARTICLES(R). The U.S. Patent and Trademark Office (USPTO) has issued United States Patent No. 8,580,297 (the "US '297 patent"
broadly covering the composition of matter and uses of novel conjugated amphoteric-amphiphilic molecules for delivery of nucleic acid-based therapeutics to control gene expression. In addition, the Japan Patent Office (JPO) has granted the claims in SMARTICLES(R) JP Application 2009-531787 (the "JP '787 application" broadly covering the combination of an anionic amphiphile, a cationic amphiphile, and a neutral amphiphile with parameters that cover a wide range of liposomal compositions. SMARTICLES is currently in clinical development delivering both a single-stranded and a double-stranded oligonucleotide through licensees ProNAi Therapeutics, Inc. and Mirna Therapeutics, Inc., respectively. Marina Biotech Announces Organizational Changes
Marketwire - Fri Jan 03, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that Philip C. Ranker will join the Marina Biotech Board of Directors and that Richard T. Ho, M.D., Ph.D., will become the Chair of the Marina Biotech Scientific Advisory Board. Further, in an on-going effort to conserve resources as the company focuses on near term pharma collaboration opportunities, Mr. Ranker and Dr. Ho have resigned from their respective positions, Interim Chief Financial Officer and Executive Vice President, Research and Development, to pursue other opportunities. The finance function of the company will transition to an outside service provider.
Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics
Marketwire - Thu Jan 02, 6:30AM CST
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology. Under terms of the amendment, Mirna paid certain pre-payments to Marina Biotech and now has additional rights to its lead program, MRX34, currently in Phase 1 clinical development for patients with unresectable primary liver cancer or metastatic cancer with liver involvement. In addition, under the terms of the license agreement, Mirna has optioned exclusivity on several additional miRNA targets. Further terms of the Agreement were not disclosed.
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Marina Biotech Monetizes UNA Intellectual Property Estate Through Agreement With Arcturus Therapeutics
Marketwire - Wed Aug 14, 6:00AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA)
Myotonic Dystrophy - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zlztxh/myotonic) has announced the addition of the "Myotonic Dystrophy - Pipeline Review, H1 2013" report to their offering. 'Myotonic Dystrophy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myotonic Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myotonic Dystrophy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Myotonic Dystrophy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Myotonic D
Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34
Marketwire - Mon May 13, 7:01AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.
